Abstract The liver has the amazing capacity to repair itself after injury; however, the same processes that are involved in liver regeneration after acute injury can cause serious consequences during chronic liver injury. In an effort to repair damage, activated hepatic stellate cells trigger a cascade of events that lead to deposition and accumulation of extracellular matrix components causing the progressive replacement of the liver parenchyma by scar tissue, thus resulting in fibrosis. Although fibrosis occurs as a result of many chronic liver diseases, the molecular mechanisms involved depend on the underlying etiology. Since studying liver fibrosis in human subjects is complicated by many factors, mouse models of liver fibrosis that mimic the human conditions fill this void. This review summarizes the general mouse models of liver fibrosis and mouse models that mimic specific human disease conditions that result in liver fibrosis. Additionally, recent progress that has been made in understanding the molecular mechanisms involved in the fibrogenic processes of each of the human disease conditions is highlighted.
Introduction
The repeated insult that occurs during the progression of many chronic liver diseases continuously activates the wound healing response; it is this chronic activation of the wound healing response that causes liver fibrosis [1, 2] . The activation of hepatic stellate cells (HSCs), which are the main collagen-producing cell in the liver, is a pivotal event during liver fibrogenesis. Provoked by chronic liver injury, activated HSCs display a myofibroblast phenotype and exhibit fibrogenic potential [1] [2] [3] . Activated HSCs set in motion a cascade of molecular, cellular, and tissue events that lead to the deposition and accumulation of extracellular matrix (ECM) components, especially collagen, to limit hepatic damage observed in chronic liver diseases [3] [4] [5] [6] . However, the accumulation of collagen and other ECM components that occurs in chronic hepatic injury results in the progressive replacement of the liver parenchyma by scar tissue, thus resulting in fibrosis [1] .
While liver fibrosis is the outcome of many different chronic liver diseases including chronic hepatitis C virus (HCV) infection, alcoholic steatohepatitis (ASH), nonalcoholic steatohepatitis (NASH), and autoimmune liver diseases, the pathogenesis of liver fibrosis depends on the underlying etiology [1, 2] . Therefore, liver fibrogenesis must be studied in the context of each of the chronic liver diseases that result in fibrosis. Mouse models of liver fibrosis that mimic human liver fibrosis have contributed to this need and have greatly enhanced the study of liver fibrosis [7, 8] .
Rodent models can address specific questions that are difficult to address in human studies. Due to the lack of an early diagnosis of liver fibrosis in human subjects and the invasive nature of liver biopsies, which is the standard for liver fibrosis assessment, multiple sampling at different stages of liver fibrogenesis in humans is challenging. However, mouse models provide researchers with the opportunity to conduct studies using multiple samples and at different stages of liver fibrogenesis [8] . The use of mice has the advantage that the whole organ and organism is intact, which is one of the limitations of in vitro studies with human tissues or cell lines [8] . Finally, genetic studies using knockout mice or the ability to knockdown specific genes can be used to determine the role of these genes in the progression of liver fibrosis [8] .
Although the use of mouse models in the study of liver fibrosis is a powerful tool, these models are not without their disadvantages. Most notably, there is a lack of an appropriate mouse model for liver fibrosis caused by alcohol abuse and chronic HCV infection [8] . Also, there are species differences between humans and mice in the immune response, gene regulation, and metabolic, pharmacological, and tissue responses [8] .
Despite these limitations, liver fibrosis research using both human subjects and mouse models has seen countless advancements in recent years. The purpose of this review article is to discuss some of the most recent advances in the study of liver fibrosis and to specifically parallel the advancements in mouse models of liver fibrosis to their human liver fibrosis counterparts.
General Mouse Models of Liver Fibrosis

Repetitive Toxic Insults
Carbon Tetrachloride
Carbon tetrachloride (CCl 4 ) is a hepatic toxin that is commonly used to induce toxic liver injury in mice. CCl 4 is converted to a free radical by reductive dehalogenation catalyzed by cytochrome p450 2E1 (CYP2E1) in hepatocytes, which induces lipid peroxidation and membrane damage that causes centralobular necrosis [9] [10] [11] [55] [56] [57] [58] [59] [60] . Using the D-GalN injury model, the Thy 1? cells would differentiate into hepatocytes and cholangiocytes on day 2 and 3 of hepatic injury to aid in the recovery process [61] .
Methione and Choline Deficient (MCD) and CholineDeficient L-Amino Acid Defined Diet (CDAA)
The methionine and choline deficient diet (MCD) is a common dietary mouse model that is used for studying the pathophysiology of NASH [21] . The diet contains about 40 % of high sucrose and 10 % of high fat. This diet lacks methionine and choline, which are required in mitochondrial b-oxidation and synthesis of low-density lipoprotein (LDL) [62] . It can cause more ROS, mitochondrial DNA damage, and apoptosis compared to other NASH models [63] . Wistar rats are more susceptible to this diet, but LongEvans and Sprague-Dawley rats are also used in presenting steatosis [64] . The disadvantage regarding this model is that the metabolic profile has differences compared to human NASH [65] [66] [67] .
Recent studies using the MCD diet model have elucidated factors involved in the progression or reduction of NASH. Mesenchymal epithelial transition factor (c-met) receptor signaling has been shown to activate anti-apoptotic pathways in hepatocytes (74) . Caspases, most recently Caspase 3, have been shown to be involved in the proapoptotic and proinflammatory processes in NASH (75) . Finally, a therapeutic study was done regarding Sitaglipin in MCD fed mice. Sitagliptin showed attenuation of hepatic steatosis, inflammation, and fibrosis insinuating future therapy application [68 • ]. However, the next step would be to check long-term side effect profiles of Sitagliptin in NASH mouse models.
Choline-deficient L-amino-acid-defined (CDAA) is a well-known dietary model that induces pathogenesis related to NASH. During continuous consumption of a CDAA diet, animal models have shown induction of steatosis, lobular inflammation, and fibrosis [69, 70] . In one study, CDAA fed Wistar rats continued to have fibrosis even after reverting back to a choline sufficient diet, but the steatosis and lobular inflammation improved. The persistent fibrosis was likely due to the hypoxic damage and oxidative stress the CDAA diet caused (79) . Choline is an essential nutrient that is involved in VLDL production via phosphatidylcholine. Without choline, hepatic lipidosis can occur causing a decrease in lipid and cholesterol excretion [71] [72] [73] .
Choline deficiency can also cause oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress. Consequently, the animal model is more susceptible to hypoxic damage resulting in significant hepatocellular death [71, 74, 75] . Lack of choline can also cause induction of a proinflammatory cascade that eventually activates HSC causing fibrosis [76, 77] .
Mouse Models that Mimic Specific Human Diseases
Autoimmune Fibrosis
Primary Biliary Cirrhosis (PBC)
PBC is a chronic cholestatic liver disease that predominantly affects middle age women [78] . Intrahepatic small bile ducts are progressively destroyed by an immunemediated attack and the disease may slowly progress until liver cirrhosis. PBC is considered an autoimmune disease. Antimitochondrial antibodies (AMAs) directed against the E2 component of the pyruvate dehydrogenase complex (PDC-E2) are present in the sera of about 95 % of the patients, and are detectable years before the appearance of clinical symptoms [78] [79] [80] .
Animal models of PBC aim to specifically recapitulate the complex pathophysiological characteristics of the human disease. Despite remarkable advances in the last decade, to date none of the proposed models can perfectly resemble the complexity of the human disease.
Murine models of PBC can be divided into spontaneous models, if biliary alterations appear in genetically modified animals without additional interventions, and induced models, in which biliary damage appears after breakdown of tolerance to PDC. Koarada et al. described the NOD.c3c4 congenic mouse as the first spontaneous model for autoimmune biliary diseases [81, 82] . NOD.c3c4 mice develop lymphocytic peribiliary infiltrates, autoantibodies, and progressive cholestasis [81] . The full-blown disease is present in 50 % of the females and in 25 % of male within 1 year of age [83] . Moreover, 55 % of the NOD.c3c4 mice develop antibodies against the PDC-E2 complex before the biliary lesions are completely formed. The microscopic alterations in the liver include the infiltration of CD3?, CD4?, and CD8? T cells with sporadic formation of granulomas [83] . Despite the fact that NOD.c3c4 mice recapitulate several features of the human disease, the appearance of alterations that are not found in PBC patients is reported too. Biliary cysts in the intrahepatic bile ducts develop in the majority of the animals, and seem related to a B cells response [84] . Moreover, unlike PBC, common bile duct dilatation is also present in NOD.c3c4 mice [83] .
An alternative model for PBC is the dominant-negative TGF-b receptor II (dnTGF-bRII) mouse [85] . CD4
? and CD8
? T cells of dnTGF-bRII mice over-express a mutated form of the TGF-bRII that is incapable of signal transduction. As a result, the immune homeostasis is altered and clusters of immune cells infiltrate the liver parenchyma [86] . Gershwin and coworkers showed that dnTGF-bRII mice develop several features of human PBC, including spontaneous production of antimitocondrial antibodies to PDC-E2, CD4
? , and CD8 ? T cells infiltration within the portal tract of 6-to 7-month-old mice, and increased levels of IFN-c, TNF-a, IL-6, and IL-12p40 [85, 87] . However, the general dysregulation of self-tolerance in dnTGF-bRII mice should not be overlooked. In fact, starting from 3 to 4 months of age, dnTGF-bRII mice develop a wasting syndrome associated with diarrhea due to marked to severe inflammatory bowel disease, with infiltration of lymphocytes, macrophages, and plasma cells in the gut [86] . Mild inflammatory infiltrates appear also in the lungs, stomach, duodenum, pancreas, and kidney [86] . The development of cholangitis in dnTGF-bRII mice does not seem to be related to abnormalities of the biliary tree. Indeed, bile duct inflammation occurs also if splenocytes of dnTGF-bRII mice are transferred into recombinase-deficient (Rag1 -/-) mice, which lack a diversified B and T cell receptor repertoire [88] . In addition, CD8
? T cells seem to be the primary effectors of the inflammation [88] .
The importance of immune regulation in the pathogenesis of PBC has been further emphasized in a subsequent murine model, the IL-2Ra -/-mouse. Wakabayashi et al. reported the development of autoimmune cholangitis and AMAs in IL-2Ra -/-mice [89] . However, severe anemia, lymphoproliferative disorders, and inflammatory bowel disease are prevalent in these mice, especially after 2 months of age [90] . Similar to dnTGF-bRII mice, CD8
? T cells have been involved in the pathogenesis of the biliary injury, while CD4
? T cells are responsible for the colitis [91] . The AE2
-/-mouse is considered an additional mouse model of PBC [92] . The anion exchanger (AE) 2 is a Cl -/ HCO 3 -exchanger expressed in different cells, where it regulates the intracellular pH [93] . In cholangiocytes, AE2 is located at the apical membrane and is the main transporter responsible for bicarbonate secretion in bile [94] . At 15 months of age, most of AE2 -/-mice develop AMAs against the PDC-E2 inner lipoyl domain, increased alkaline phosphatase levels in plasma and different degrees of portal inflammation. However, the liver damage is not progressive, a slight fibrosis is reported only in mice with florid portal infiltrates, and there are no gender differences [92] . Together with the liver phenotype, AE2
-/-mice develop alterations in the immune system. Enlarged spleen, reduced CD4
? /CD8
? ratio, and altered cytokine production have been described in AE2 -/-mice, possibly as a consequence of defective pH regulation in immune cells [92, 95] . Interestingly, natural regulatory T cells (Tregs) are also reduced in this mouse model. This finding is in accordance with what has been described in PBC patients [96] and in dnTGF-bRII and IL2Ra
-/-models [85, 89] , underlying an important pathogenic role of loss of tolerance in PBC.
The induced mouse models of PBC rely on the breakdown of tolerance to PDC, the mitochondrial autoantigen against which AMA are directed. Jones et al. reported that immunization of SJL/L mice with intraperitoneal injections of bovine PDC-E2 emulsified in complete Freund's adjuvant containing 10 mg/ml of Mycobacterium tuberculosis is able to induce AMA formation and non-suppurative destructive cholangitis [97, 98] . Some authors have, however, questioned the specificity of the immune response in SJL/L mice [99, 100] . Recently, an additional model for PBC has been successfully induced by the immunization of mice with 2-octynoic acid (2OA) coupled to bovine serum albumin [101] . Immunized mice manifest typical autoantibody formation and cholangitis but fail to develop fibrosis. 2OA is a chemically synthetized compound which is widely present in cosmetic products. This model offers, therefore, an intriguing conceptual support to an environmental origin of PBC [101] . To this extent, previous work showed that xenobiotic modification of PDC-E2 is able to generate new antigens that react with the autoantibodies present in PBC sera [102] .
In conclusion, considerable advances in the understanding of PBC pathophysiology have been made in recent years through the study of animal models [103] . Since UDCA still represent the only recommended medical treatment for PBC, murine models offer also the possibility to evaluate potential new drugs. Different compounds have indeed shown promising effects in attenuating the biliary damage in a number of PBC models, suggesting new therapeutic approaches that deserve further studies [104 • , 105] .
Primary Sclerosing Cholangitis (PSC)
Primary sclerosing cholangitis (PSC), first described in the mid-1850s is characterized grossly by chronic cholestasis accompanied by inflammation of the biliary epithelium resulting in multifocal biliary strictures. PSC is asymptomatic in 50 % of the diagnosed patients [106] .
Diagnosis of PSC is made through liver enzyme assessment where the most commonly dysregulated candidate is alkaline phosphatase. Total bilirubin remains normal in most of the cases, whereas the level of amino transferases is elevated in a very small number of patients [107] . One of the major risk factors contributing to the development of PSC is inflammatory bowel disease [108] . A multitude of factors have been deemed responsible for the development and progression of this disease. Considering the heterogeneity of PSC and all the variable factors contributing to this disease, a single animal model mimicking human PSC is hard to develop. Hence, there are a few different models that are used to study the mechanisms involved PSC pathogenesis.
MDR2 -/-
Liver cirrhosis resulting from chronic cholangiopathies such as PSC is marked by a massive increase in liver fibrosis. The MDR2 -/-mice develop severe biliary fibrosis, and thus have been used has a model of liver fibrogenesis in PSC [109] .
Decreased phosphatidylcholine in the bile of MDR2
-/-mice might potentiate the toxicity of other bile acids. It is a multistep process where there is leakage of bile (from disrupted tight junctions and basement membranes of bile ducts) into portal tracts causing inflammation and fibrosis [110] . Fibrosis in MDR2 -/-mice is caused by a timedependent alteration in expression of pro-and anti-fibrotic genes [109, 110] . The inflammatory response in MDR2 -/-mice varies according to the age of the animal, although there is over-expression of at least some factors such as TNF-a, IL-1b, Il-6, TGF-b1, and IFN-c when compared to MDR2
?/? control mice. The MDR2 -/-animals can thus serve as a good model to intervene for developing treatment strategies to tackle the fibrotic response in PSC. norUDCA or UDCA treatment has already proved to ameliorate fibrosis in PSC models, though controversies exist in regard to their applicability in human subjects [111] .
CFTR Mutation
Mouse models with mutations in the exon 10 of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene have been shown to develop focal cholangitis and biliary cirrhosis [112] . Specifically, loss of function of the CFTR gene in BEC results in decreased bile flow and alkalinization in subjects with CF. In a study to evaluate the role of CFTR gene in development of cholangitis, mice with disrupted CFTR gene (cftr -/-) were fed Dextran sodium sulfate (DSS) to induce colitis. DSS caused biliary damage and portal inflammation as displayed by enhanced ductular reaction and high reactivity of cholangiocytes (isolated from the cftr -/-mice) toward LPS treatment [113] . After DSS treatment, intestinal permeability to microbial products as well as endotoxins is increased which reach the liver via portal circulation resulting in inflammation and fibrosis [114, 115] . Taken together, these results suggest that the CFTR mutation is not the only cause for biliary cirrhosis and portal hypertension. This is statistically supported by patient data where it is found that among patients with CF disorder, about 40 % display abnormal hepatic imaging and biochemistry and among which only 5-10 % develop focal biliary cirrhosis and portal hypertension [116] . This is an indication that CFTR dysfunction predisposes to liver diseases.
3,5-Diethoxycarbonyl-1,4-Dihydrocholine (DDC)
To study the pathological alterations occurring in the earlier phases of PBC and PSC, a slowly progressing model is essential. Fickert and colleagues have demonstrated that continuous feeding of 3,5-diethoxycarbonyl-1,4-dihydrocholidine (DDC) induced chronic cholangiopathy that progressed slowly over a period of time. Mice fed with this xenobiotic agent for a week showed ductal proliferation, which progressed slowly over time, and by 4 weeks post treatment the bile ducts contained pigment plugs. The intraductal plugs showed autofluorescence generated from biliary protoporphyrin secretion [117] . Infiltration of neutrophils around both large and small bile ducts, an increase in serum transaminases and an induction of reactive phenotype of the BEC was also observed in the DDC fed mice. Recently, morphological studies confirmed hepatocellular necrosis and phagocytosis of these necrotic cells by Kupffer cells and showed compensatory hepatocyte proliferation in response to DDC-induced injury. This study also revealed that bile canalicular abnormalities occur prior to ductular reactions and periductal fibrosis in this novel xenobiotic-induced model of primary sclerosing cholangitis [118 •• ] . This was the first study showing these characteristics associated with progression of PSC.
Autoimmune Hepatitis (AIH)
Autoimmune hepatitis (AIH) is a form of chronic hepatitis. It is characterized by histological findings (most commonly interface hepatitis), elevated serum aminotransferases, hypergammaglobulinemia, and seropositivity for ANA, anti-LKM-1, and SMA, after the exclusion of other causes of chronic hepatitis [119] . It is important to exclude other causes of chronic hepatitis by checking viral serologies, obtaining a good history for substance abuse including alcohol, and ruling out biliary sources of chronic hepatitis. Disease severity can range from asymptomatic hepatitis [120] to severe, fulminant hepatic failure [121] . Although the cause of AIH remains unknown, the working model of pathogenesis is recognition of self-antigen or autoantibody/ antigen complexes by CD4
? T cells [122] resulting in loss of tolerance and progressive necroinflammation and fibrosis in a host with genetic pre-disposition [123] . HLA genes have increasingly been implicated in the genetic link of AIH [123] .
Cytokines, specifically TGF-b, have been shown in murine models to play a large role in immune tolerance. TGF-b is secreted by phagocytes that are exposed to apoptotic T cells. This contributes to immune tolerance by inducing CD4 ? Foxp3 ? regulatory T cells via CD3-specific antibody [124] . Additionally, TGF-b is found to have increased expression in hepatic inflammation. This overexpression is thought to play a role in the suppression of an autoimmune response. Impairment of this signaling pathway has been shown to increase susceptibility of AIH based on histological findings in murine models [125] . This pathway has, therefore, been used to produce animal models of AIH. TGF-b1 -/-mice spontaneously develop necroinflammatory hepatitis recapitulating human aspects of AIH [126, 127] .
Conclusion
Liver fibrosis is the consequence of many chronic liver diseases and regardless of the etiology is the result of a highly coordinated process. Murine models of liver fibrosis recapitulating fibrogenesis in human liver disease conditions are valuable tools for studying the fibrogenic process of specific diseases. Although recent advances have been made in understanding the molecular mechanisms involved in fibrogenesis and in discovering novel tools that can aid in the diagnosis and treatment of liver fibrosis, additional studies are still needed. Specifically, the efficacy of these diagnostics and therapeutics in human patients still needs to be explored. 
